{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T14:49:45Z","timestamp":1744901385428},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.6435","type":"journal-article","created":{"date-parts":[[2016,11,14]],"date-time":"2016-11-14T22:09:35Z","timestamp":1479161375000},"page":"3351-3356","source":"Crossref","is-referenced-by-count":1,"title":["Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis"],"prefix":"10.2169","volume":"55","author":[{"given":"Shuichiro","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Hematology, Hokkaido University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Tsumanuma","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsumasa","family":"Osakabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Nursing, Yamagata Prefectural University of Health Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ejiro","family":"Omoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yamagata Prefectural Central Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Bain BJ, Clark DM, Lampert IA, Wilkins BS. Chronic myeloproliferative and myeloproliferative\/myelodysplastic disorders. In: Bone Marrow Pathology. 3rd ed. Bain BJ, Clark DM, Lampert IA, Wilkins BS, Eds. John Wiley & Sons, London, 2008: 191-230."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23: 8520-8530, 2005.","DOI":"10.1200\/JCO.2004.00.9316"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lambertenghi-Deliliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinic-pathological entity. Br J Haematol 28: 161-166, 1991.","DOI":"10.1111\/j.1365-2141.1991.tb04411.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Verhoef GE, De Wolf-Peeters C, Ferrant A, et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 63: 235-241, 1991.","DOI":"10.1007\/BF01698371"},{"key":"5","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"5. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90: 1128-1132, 2005.","journal-title":"Haematologica","ISSN":"http:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"6. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454-2465, 2012.","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11: 945-956, 2005.","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Della Porta MG, Malcovati L. Myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96: 180-183, 2011.","DOI":"10.3324\/haematol.2010.039875"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yoshihara S, Ikegame K, Taniguchi K, et al. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transplant 47: 369-373, 2012.","DOI":"10.1038\/bmt.2011.84"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Kr\u00f6ger N, Zabelina T, van Biezen A, et al; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96: 291-297, 2011.","DOI":"10.3324\/haematol.2010.031229"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Scott BL, Storer BE, Greene JE, Hackman RC, Appelbaum FR, Deeg HJ. Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia. Biol Blood Marrow Transplant 13: 345-354, 2007.","DOI":"10.1016\/j.bbmt.2006.10.030"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16: 358-367, 2010.","DOI":"10.1016\/j.bbmt.2009.10.025"},{"key":"13","unstructured":"13. Udomsakudi-Auewarakul C, Visuhisakchai S, Sangruchi T, Issaragrisil S. Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogenic peripheral blood stem cell transplantation. Asian Pac J Allergy Immunol 21: 121-126, 2003."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sale GE, Deeg HJ, Porter BA. Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 12: 1285-1294, 2006.","DOI":"10.1016\/j.bbmt.2006.07.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kerbauy DM, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocytopenia. Biol Blood Marrow Transplant 13: 355-365, 2007.","DOI":"10.1016\/j.bbmt.2006.11.004"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99: 2255-2258, 2002.","DOI":"10.1182\/blood.V99.6.2255"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ballen K. How to manage the transplant question in myelofibrosis? Blood Cancer J 2: e59, 2012.","DOI":"10.1038\/bcj.2012.3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Brunstain CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 211: 282-286, 2011.","DOI":"10.1182\/blood-2011-03-344853"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Takagi S, Ota Y, Uchida N, et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood 116: 649-652, 2010.","DOI":"10.1182\/blood-2009-11-252601"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 19: 117-122, 2013.","DOI":"10.1016\/j.bbmt.2012.08.014"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Brodsky RA, Luznik L, Bola\u00f1os-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant 42: 523-527, 2008.","DOI":"10.1038\/bmt.2008.203"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/22\/55_55.6435\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T03:34:07Z","timestamp":1498361647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/22\/55_55.6435\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.6435","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}